There are many types of T-cell lymphoma, just as there are many B-cell types of lymphoma. Although this page appears grouped with the other aggressive forms of NHL there are also indolent T-cell types so if you don't see your type here, look in the indolent lymphoma section. This page is simply a collection of authoritative articles about many types of T-cell lymphoma and no one type in specific. Our Advanced Search page lets you perform a focused search of a specific type from prestigious medical journals.
There is still no consensus about whether T-cell lymphomas respond as well to treatment as their corresponding B-cell types. Most experts will agree that they remain a challenge to treat.
Here are some excellent articles that discuss T-cell lymphomas in-depth.
This first link is to a webcast from Jasmine Zain, MD Columbia University Medical Center, New York.(Approx 45 minutes long)
Next we have The CancerNetworks latest series about T-cell lymphomas.
Next we have Grand Rounds in Hematology newsletter from Bloodline.
Topics covered in the above newsletter include:
The Cancer network's T-cell lymphoma series.
From the prestigious journal Blood, this next link is a thorough review of all the peripheral T-cell lymphomas. It discusses their pathology and biology, what the prognosis is for the various types, and current and new treatment strategies. It is a must read for anyone wishing to learn about peripheral T-cell lymphoma.
Next is a review of the status of using stem cell transplants in the treatment of T-cell lymphoma, from the journal, Annals of Oncology.
The following is from Blood journal.
Below is an article from the ASH education series that reviews the biology, prognosis and treatment options for T-cell lymphomas, with an emphasis on peripheral T-cell types.
The following article from the Blood Journal explores how the type of skin erruption is a prognostic factor in cutaneous Adult T-cell Lymphoma/Leukaemia
Another important new treatment is Pralatrexate. The recently published PROPEL clinical trial showed a 27% response rate in patients with relapsed or refractory Peripheral T-cell lymphoma. Click the link below to read the study.